Characterization of anti-human Granzyme B monoclonal antibody 10C11

已经证明，颗粒酶B（Gzm B），一种细胞毒性丝氨酸蛋白酶，在受 老化和慢性炎症，并导致完整性降低和伤口愈合受损。GzmB是一个 一个由五种丝氨酸蛋白酶组成的家族，现在正成为药物开发的关键目标。基于这些 研究发现，以研究为基础的生物技术公司维达Therapeutics正在开发一套“一流的 抑制GzmB作用的药物（小分子和生物），设计用于多种途径的 本发明提供了用于治疗各种炎性和年龄相关病症的药物组合物。为了研究生物学的影响 维达获得了抗人GzmB单克隆抗体10 C11（在兔体内培养 针对纯化的人GzmB），并且希望在进行针对人GzmB的免疫前首先完全表征抗体。 动物实验目前，维达没有资源或专业知识来充分表征抗体， 我想寻求不列颠哥伦比亚省大学的Jamie Piret博士的帮助，使用NSERC-Engage 允许进行所需的表征。

It has been demonstrated that granzyme B (GzmB), a cytotoxic serine protease, accumulates in tissues affected by aging and chronic inflammation and contributes to reduced integrity and impaired wound healing. GzmB is one of a family of five serine proteases that are now emerging as key targets for drug development. Based on these findings, the research based biotechnology company, viDA Therapeutics is developing a suite of 'first-in-class drugs' (small molecule and biological) that inhibit the action of GzmB designed for multiple routes of administration to treat the various inflammatory and age related conditions. To pursue the effects of biological inhibition of GzmB, viDA has acquired the anti-human GzmB monoclonal antibody 10C11 (raised in rabbits against purified human GzmB) and would like to first completely characterize the antibody before conducting animal trials. At present viDA does not have the resources or expertise to fully characterize the antibody and would like to enlist the help of Dr. Jamie Piret at the University of British Columbia using a NSERC-Engage grant to carry out the required characterization.